News

Exposure-safety analyses are often a great complement to exposure-response analyses in order to drive key MIDD decisions such as therapeutic dose selection. In this example, our colleague Celine Sarr and collaborators from

We are happy to have Linda Hafdell onboard as a contract manager. Linda’s previous work experience mainly consists of public procurement within the fields of IT, scientific instruments and other services. She

We are happy to welcome Eric Salgado to our growing PBPK team as an Associate Consultant. Eric’s research experience includes PBPK/TMDD modeling of monoclonal antibodies in tumors and tumor-draining lymph nodes as

We are currently refining and developing our internal training course curriculum for the remainder of 2021 into 2022. We can also reflect upon the courses delivered during the first half of 2021.

We are thrilled to have Anna on board as an Associate Consultant. Her experience includes PK modeling and simulations for dosing individualization of antibodies and small molecules, and her publications include a

Pharmetheus is proud to have held a PK-Sim/MoBi workshop at the FDA. As members of the Open System Pharmacology Suite management team and of the scientific community, we partnered together with the

We are happy to welcome Maddlie Bardol to our growing team. Maddlie’s research experience includes population PK/PD modelling of analgesics and sedatives and dose optimization in children. Maddlie will take on a role as an associate consultant at